EMA Authorised: Remicade (infliximab) — Janssen Cilag International NV

View source ↗

Summary

The EMA has authorised Remicade (infliximab) for multiple inflammatory diseases under Janssen Cilag International NV as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Crohn Disease
• Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis

Drugs mentioned

• Remicade (infliximab)

Snippet

Status: Authorised. Therapeutic area: Spondylitis, Ankylosing;Arthritis, Rheumatoid;Psoriasis;Crohn Disease;Arthritis, Psoriatic;Colitis, Ulcerative. MAH: Janssen Cilag International NV. Decision date: 26/11/2025